OTCPK:STNN

Stock Analysis Report

Executive Summary

EPHS Holdings, Inc., through its subsidiary, Emerald Plants Health Source Inc., produces cannabis for medical use.

Snowflake

Fundamentals

Weak fundamentals or lack of information.

Share Price & News

How has EPHS Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

STNN

-0.05%

US Pharmaceuticals

0.4%

US Market


1 Year Return

-79.5%

STNN

-8.0%

US Pharmaceuticals

6.9%

US Market

Return vs Industry: STNN underperformed the US Pharmaceuticals industry which returned -8% over the past year.

Return vs Market: STNN underperformed the US Market which returned 6.9% over the past year.


Shareholder returns

STNNIndustryMarket
7 Day0%-0.05%0.4%
30 Day25.0%-0.4%-1.2%
90 Day-32.8%-1.7%-0.4%
1 Year-79.5%-79.5%-5.8%-8.0%9.3%6.9%
3 Yearn/a18.3%10.0%45.8%36.4%
5 Yearn/a22.1%9.2%62.9%45.1%

Price Volatility Vs. Market

How volatile is EPHS Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is EPHS Holdings undervalued compared to its fair value and its price relative to the market?

36.78x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate STNN's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate STNN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: STNN is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: STNN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate STNN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: STNN is overvalued based on its PB Ratio (36.8x) compared to the US Pharmaceuticals industry average (2.9x).


Next Steps

Future Growth

How is EPHS Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

14.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as EPHS Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has EPHS Holdings performed over the past 5 years?

-805.6%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: STNN is unprofitable, and there is insufficient past data to establish if their past 5-year earnings growth rate was positive.

Accelerating Growth: Unable to compare STNN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: STNN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (24.3%).


Return on Equity

High ROE: STNN has a negative Return on Equity (-278.97%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: STNN is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: STNN is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is EPHS Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: STNN's short term assets ($175.9K) do not cover its short term liabilities ($629.5K)

Long Term Liabilities: STNN's short term assets (175.9K) do not cover its long term liabilities (1.6M)


Debt to Equity History and Analysis

Debt Level: STNN's debt to equity ratio (195.5%) is considered high

Reducing Debt: Insufficient data to determine if STNN's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: STNN has a high level of physical assets or inventory.

Debt Coverage by Assets: STNN's debt is not covered by short term assets (assets are 0.1x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: STNN has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: STNN has less than a year of cash runway if free cash flow continues to reduce at historical rates of -108.4% each year


Next Steps

Dividend

What is EPHS Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate STNN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate STNN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if STNN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if STNN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of STNN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of EPHS Holdings's salary, the management and board of directors tenure and is there insider trading?


CEO

EPHS Holdings has no CEO, or we have no data on them.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team


    Board Members

      Company Information

      EPHS Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


      Key Information

      • Name: EPHS Holdings, Inc.
      • Ticker: STNN
      • Exchange: OTCPK
      • Founded:
      • Industry: Pharmaceuticals
      • Sector: Pharmaceuticals & Biotech
      • Market Cap: US$33.485m
      • Shares outstanding: 74.41m
      • Website: https://www.ephsholdings.com

      Number of Employees


      Location

      • EPHS Holdings, Inc.
      • 5490 Notre Dame Est
      • Montreal
      • Quebec
      • H1N 2C4
      • Canada

      Listings

      TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
      STNNOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDFeb 2018

      Biography

      EPHS Holdings, Inc., through its subsidiary, Emerald Plants Health Source Inc., produces cannabis for medical use. The company is based in Montreal, Canada. 


      Company Analysis and Financial Data Status

      All financial data provided by Standard & Poor's Capital IQ.
      DataLast Updated (UTC time)
      Company Analysis2019/10/19 00:36
      End of Day Share Price2019/10/18 00:00
      Earnings2019/06/30
      Annual Earnings2018/12/31


      Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.